Table 2.
Proportion of patients that produced levels above the calculated optimal cut-off values after SLA stimulation of a whole blood sample.
| Analytes (cut-off value) | L. donovani | L. infantum | ||||
|---|---|---|---|---|---|---|
| D0 N (%) |
W1 N (%) |
EOT N (%) |
D0 N (%) |
W1 N (%) |
EOT N (%) |
|
| IFN-γ (48.1 pg/ml) | 4/13 (31) | 10/13 (77) | 13/13 (100) | 4/13 (31) | 10/13 (77) | 13/13 (100) |
| TNF-α (25.4 pg/ml) | 4/13 (31) | 9/13 (69) | 10/13 (77) | 4/13 (31) | 10/13 (77) | 11/13 (85) |
| IP-10 (452.9 pg/ml) | 3/13 (23) | 11/13 (85) | 12/13 (92) | 3/13 (23) | 9/13 (69) | 12/13 (92) |
| IL-2 (20.0 pg/ml) | 0/13 (0) | 0/13 (0) | 5/13 (38) | 0/13 (0) | 0/13 (0) | 5/13 (38) |
| IL-10 (37.3 pg/ml) | 5/13 (38) | 5/13 (38) | 4/13 (31) | 3/13 (23) | 5/13 (38) | 5/13 (38) |
D0: active moment, day zero; W1: first week of the treatment; EOT: end of treatment; N: number of patients; %: percentage of positives patients that produce cytokines/chemokines.